Skip to content
Screener

Financing Cash Flow at other companies

Pfizer logo
PfizerPFE
-$2.86B+45.4%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$7.92M+751%
AbbVie logo
AbbVieABBV
$919M+173%
Immunome logo
ImmunomeIMNM
-$135K-100%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$16M-69.2%
CTO
Citius Oncology, Inc.CTOR
$15.13M+299%

Other financials

Income statement

See full
Revenue-
Gross profit-
Operating income-$9.3M-52.6%
Net income-$8.4M-44.6%
EPS (diluted)-$0.05+28.6%

Balance sheet

See full
Cash & equivalents$107.1M+277%
Total debt$871.0K+0.1%
Total equity$107.4M+287%
Total assets$114.2M+227%

Cash flow

See full
Operating cash flow-$8.8M+2.5%

Valuation

See full
Market cap$2.3B+1,350%
Enterprise value$2.19B+1,537%

Profitability

See full
Gross margin90%-7.4pp
Operating margin-4,195%-4,591pp
Net margin-4,130.1%-4,444pp
FCF margin-300.5%

Returns & leverage

See full
Return on equity-43.6%-17.9pp
Debt / equity0.0×
Current ratio17.2×+12.6×

Where this comes from

Reported directly by SELLAS Life Sciences Group, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: SELLAS Life Sciences Group, Inc.’s 10-Q, filed May 12, 2026.

Filed
May 12, 2026, 4:01 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001390478-26-000008
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Proceeds from the exercise of common stock warrants44,084503
Proceeds from issuance of common stock, common stock warrants, and pre-funded warrants, net of issuance costs23,030
Proceeds from employee stock purchases6648
Net cash provided by financing activities44,15023,581
Net increase in cash, cash equivalents, restricted cash, and restricted cash equivalents35,30414,511
Cash, cash equivalents, restricted cash, and restricted cash equivalents at the beginning of period71,89313,986
Cash, cash equivalents, restricted cash, and restricted cash equivalents at the end of period$107,197$28,497
Supplemental disclosure of cash flow information:

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is SELLAS Life Sciences Group, Inc.'s financing cash flow?
SELLAS Life Sciences Group, Inc. (SLS) reported financing cash flow of $44.15M in Q1 2026.
How has SELLAS Life Sciences Group, Inc.'s financing cash flow changed year-over-year?
SELLAS Life Sciences Group, Inc.'s financing cash flow increased by 87.2% year-over-year, from $23.58M to $44.15M.
What is the long-term trend for SELLAS Life Sciences Group, Inc.'s financing cash flow?
Over 4 years (2021 to 2025), SELLAS Life Sciences Group, Inc.'s financing cash flow has grown at a 63.5% compound annual growth rate (CAGR), from $12.07M to $86.3M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about SELLAS Life Sciences Group, Inc.'s financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude